2030 Compounding Diabetes 
Express Pharma
JANUARY 14, 2025
The Indian nutraceutical market is set to grow sixfold by 2030 Kalka Prasad, AVP – Marketing, Crius Life, Crius Group The Indian nutraceutical market is projected to reach $64 billion by 2030. per cent from 2024 to 2030. billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.3
Express Pharma
MAY 30, 2024
In the APAC region, several factors contribute to the increasing prevalence of neurological disorders, including ageing populations, lifestyle changes, and the rising incidence of risk factors such as hypertension and diabetes.” billion in 2030, with a compound annual growth rate (CAGR) of 117.6 These include Eisai Co.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmD Live
MAY 13, 2024
Their projections indicate that approximately 10,000 people will turn 65 each day over the next 19 years, with the population of older adults expected to double to 80 million by 2030. At this rate, nearly half of the older population could be impacted by polypharmacy by 2030. Data from the U.S. in 1994 to 42.4%
PharmaShots
APRIL 3, 2023
The P-III trial (GUARD) results showed no safety signals & were found to be well tolerated with no observed treatment-emergent serious AEs ADX-2191 is a sterile, non-compounded IVT formulation of methotrexate for specific rare retinal diseases. old, for use by women with diabetes who are pregnant & for wear time of up to 15 days.
European Pharmaceutical Review
JUNE 27, 2022
The €156 million initiative identifies effective actions and the available legal and financial supporting tools across five main areas: cardiovascular diseases, diabetes, chronic respiratory diseases, mental health and neurological disorders, as well as their main contributing factors. Did you know, 1.7
Expert insights. Personalized for you.
105 
Let's personalize your content